GLP-1 drugs for diabetes and weight loss may influence patients’ cancer risk, usually lowering it but sometimes possibly ...

Lilly’s GLP-1 matches Victoza Lilly's phase III diabetes treatment dulaglutide has matched Victoza in a head-to-head trial, which will help it make in-roads into the fiercely competitive market.

Healthcare providers often prescribe GLP-1 drugs such as semaglutide (Ozempic and Wegovy) or liraglutide (Victoza and Saxenda) for type 2 diabetes control and weight loss.

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

Most people have likely heard about the new weight-loss and diabetes management drugs called Ozempic and Mounjaro, which are also called GLP-1 medications, short for glucagon-like peptide-1 agonists, ...

GLP-1 receptor agonists show promise in treating hidradenitis suppurativa, offering significant symptom relief and improved ...

Healthcare providers often prescribe GLP-1 drugs such as semaglutide (Ozempic and Wegovy) or liraglutide (Victoza and Saxenda) for type 2 diabetes control and weight loss.

The generic product is supplied as 6 mg/mL solution in a prefilled, single-patient-use pen. Each pen delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg in 2- or 3-count package sizes.

Novo Nordisk continued to make the case for its once-weekly GLP-1 type 2 diabetes drug semaglutide at this week’s EASD conference in Lisbon, a key drug for the company once approved.

In June, the company rolled out favorable results pitting semaglutide against fellow Novo GLP-1 drug Victoza and Merck mammoth Januvia, a DPP-4 therapy, and in August, it put out a positive trial ...